title: Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines.
abstract: Breast cancer continues to be one of the leading causes of cancer mortality in the world. The treatment generally involves multiple modalities including surgery, radiation and/or chemotherapy. Anthracyclines, one of the first chemotherapeutic agents introduced in the 1960s, has been the backbone for the last 30 years and has been used extensively so far. However, the cardiac toxicity and the concern for secondary hematological malignancy has always been a challenge. A better understanding of the tumor biology, role of Her2 expression and the discovery of trastuzumab and other anti-Her 2 agents along with other effective novel therapeutic options, have revolutionized the treatment for breast cancer. The role of anthracyclines has come under close scrutiny, especially in the adjuvant setting for patients with early stage breast cancer and those with low or intermediate risk of disease recurrence. Recent studies have highlighted such a shift in the use of anthracyclines in both the academic and community clinical practice. However, in patients with a high risk of relapse, anthracyclines still hold promise. Ongoing clinical trials are underway to further define the role of anthracyclines in such a patient population. This review highlights the development, clinical utility, limitations and potential future use of anthracyclines in the adjuvant setting for patients with breast cancer. We consulted PubMed, Scopus, MEDLINE, ASCO annual symposium abstracts, and http://clinicaltrials.gov/ for the purpose of this review.
authors.affiliation: Jennifer A Crozier, Abhisek Swaika, Alvaro Moreno-Aspitia, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224 , United States.
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Crozier
authors.affiliation: Jennifer A Crozier, Abhisek Swaika, Alvaro Moreno-Aspitia, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224 , United States.
authors.forename: Abhisek
authors.initials: A
authors.lastname: Swaika
authors.affiliation: Jennifer A Crozier, Abhisek Swaika, Alvaro Moreno-Aspitia, Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224 , United States.
authors.forename: Alvaro
authors.initials: A
authors.lastname: Moreno-Aspitia
keywords: Adjuvant; Anthracyclines; Breast cancer; Chemotherapy; Neoadjuvant
references.citation: J Clin Oncol. 1998 Aug;16(8):2651-8
references.pmid: 9704715
references.citation: Cancer Chemother Rep. 1974 Nov-Dec;58(6):877-82
references.pmid: 4614896
references.citation: Recent Results Cancer Res. 1978;68:98-104
references.pmid: 223207
references.citation: N Engl J Med. 1992 Jun 25;326(26):1745-51
references.pmid: 1594016
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1177-83
references.pmid: 19204201
references.citation: Lancet Oncol. 2011 Nov;12(12):1134-42
references.pmid: 21917518
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4179-91
references.pmid: 15961765
references.citation: Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):800-9
references.pmid: 22426147
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1195-204
references.pmid: 12663705
references.citation: N Engl J Med. 2002 Dec 19;347(25):1999-2009
references.pmid: 12490681
references.citation: N Engl J Med. 2011 Oct 6;365(14):1273-83
references.pmid: 21991949
references.citation: J Cancer. 2013;4(2):117-32
references.pmid: 23386910
references.citation: N Engl J Med. 2004 Dec 30;351(27):2817-26
references.pmid: 15591335
references.citation: Lancet Oncol. 2013 Oct;14(11):1121-1128
references.pmid: 24007746
references.citation: Tumori. 1974 Sep-Oct;60(5):393-416
references.pmid: 4142149
references.citation: N Engl J Med. 2005 Jun 2;352(22):2302-13
references.pmid: 15930421
references.citation: J Natl Cancer Inst. 2010 Dec 15;102(24):1845-54
references.pmid: 21098761
references.citation: Ann Oncol. 2002 May;13(5):699-709
references.pmid: 12075737
references.citation: J Clin Oncol. 2003 Apr 15;21(8):1431-9
references.pmid: 12668651
references.citation: Lancet. 2012 Feb 4;379(9814):432-44
references.pmid: 22152853
references.citation: Leukemia. 2004 Jan;18(1):120-5
references.pmid: 14586477
references.citation: J Clin Oncol. 2005 Apr 20;23(12):2716-25
references.pmid: 15837986
references.citation: J Natl Cancer Inst. 2008 Jan 2;100(1):14-20
references.pmid: 18159072
references.citation: J Clin Oncol. 2012 Jun 20;30(18):2232-9
references.pmid: 22614988
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5664-71
references.pmid: 17116941
references.citation: J Clin Oncol. 2011 Mar 1;29(7):859-67
references.pmid: 21189395
references.citation: J Clin Oncol. 2001 Feb 15;19(4):931-42
references.pmid: 11181655
references.citation: J Clin Oncol. 2012 Nov 20;30(33):4071-6
references.pmid: 22826271
references.citation: J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305
references.pmid: 22949432
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5166-70
references.pmid: 16051958
references.citation: N Engl J Med. 2008 Apr 17;358(16):1663-71
references.pmid: 18420499
references.citation: N Engl J Med. 2009 May 14;360(20):2055-65
references.pmid: 19439741
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1160-7
references.pmid: 19204204
references.citation: Oncology. 1979;36(1):40-7
references.pmid: 156337
references.citation: Circulation. 1997 Jan 21;95(2):320-3
references.pmid: 9008443
references.citation: JAMA. 2006 Apr 12;295(14):1658-67
references.pmid: 16609087
references.citation: Cancer. 2003 Jun 1;97(11):2869-79
references.pmid: 12767102
references.citation: J Clin Oncol. 1986 Dec;4(12):1748-57
references.pmid: 3783201
references.citation: JAMA. 1979 Oct 5;242(14):1509-13
references.pmid: 470088
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1223-30
references.pmid: 18227530
references.citation: Cancer Res. 2000 Apr 1;60(7):1789-92
references.pmid: 10766158
references.citation: J Clin Oncol. 2011 Sep 1;29(25):3366-73
references.pmid: 21768458
references.citation: N Engl J Med. 1994 May 5;330(18):1260-6
references.pmid: 7908410
references.citation: Ann Oncol. 2009 May;20(5):816-27
references.pmid: 19153118
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1231-8
references.pmid: 18250349
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3808-15
references.pmid: 17664460
references.citation: N Engl J Med. 2005 Oct 27;353(17):1784-92
references.pmid: 16251534
references.citation: Ann Intern Med. 1979 Nov;91(5):710-7
references.pmid: 496103